General information

Announcements(0)

Greetings from the Chair

Overview

Web abstract

Best Student Presentation Award

Selected programs of presentations in English

Registration

Registration (Non-presenters under 4th year underg

Information for Participants

Information for Presenters and Chairs

Banquet

Luncheon Seminar & Career Design Seminar

General information 2

Abstract Submission (Oral/Poster Presentation) for

Abstract Submission (Oral/Poster Presentation)

Timetable

Fri. Mar 29, 2024

Sat. Mar 30, 2024

Sun. Mar 31, 2024

Program

Sessions

Search presentations

20230323085903895_en.png

app_icon.png

Change account information such as the email address and password on the account setting screen common to Confit.

Login required to view

Password required to view

Presentation Information

Session Details

Enter the password to view the abstracts.<br><br>The password will be emailed to those who have completed the registration.

To browse or post comments, you must log in.

You cannot post comments as it is outside the comment posting period.

This comment has been deleted. You cannot reply to this comment.

Program Type

Profile management

Announcements

Bookmark

Download PDF for print

Drug development for new anticancer agents using Japanese cancer patient-derived xenograft (PDX) models

Nowadays, since the number of novel drugs created by pharmaceutical companies decreases, there is a need to activate drug discovery through academic basic research. In this sense, Japanese government has been promoting drug discovery in academia. Since then, candidate compounds in academia have increased significantly, with particularly great results in the cancer field. However, despite the facts that oncology drug discovery is an unmet medical need and a priority area for pharmaceutical companies, out-licensing from academia to companies has been halted or stagnated from the viewpoint of efficacy and other factors. On the other hand, academia has begun to develop modalities for drug species (drug discovery modalities) as peptides, nucleic acids, and antibodies, although small molecule drug still accounts for more than half of the total share of drug discovery seeds. In this symposium, we will introduce new animal models, drug discovery modalities, and drug discovery seeds, with the hope of revitalizing novel academic drug discovery to fight cancer.

Novel challenges in academic drug discovery to fight cancer disease

The 144th Annual Meeting of the Pharmaceutical Society of Japan (Yokohama)

Presentation Information

[S14-1]Drug development for new anticancer agents using Japanese cancer patient-derived xenograft (PDX) models

Password required to view